Population pharmacokinetics of netilmicin in short-term prophylactic treatment

British Journal of Clinical Pharmacology

Volumn 55, Issue 6, 2003, Pages 552-559

  Jauregizar, Nerea ^a,e   Wald, Jeff A ^b   Astobieta, Ander ^c   Rodriguez Sasiain, Jose M ^c   Lukas, John C ^a   Calvo, Rosario ^a,d  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b PHARSIGHT CORPORATION   (United States)

^c HOSPITAL DE GALDAKAO   (Spain)

^d UNIVERSITY OF WASHINGTON   (United States)

^e Edificio BEAZ   (Spain)

Author keywords

Covariate; Netilmicin; Population pharmacokinetic; WinNonMix

Indexed keywords

CREATININE; NETILMICIN;

ACCURACY; ADULT; AGED; ANALYTICAL ERROR; ARTICLE; BLOOD SAMPLING; COMPUTER PROGRAM; CONFIDENCE INTERVAL; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG INFUSION; EVALUATION; FEMALE; GENDER; HUMAN; INFECTION PREVENTION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZATION; RETROSPECTIVE STUDY; SIMULATION; SPAIN; UROLOGIC SURGERY; UROLOGY; VALIDATION PROCESS;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; FEMALE; HUMANS; MALE; MIDDLE AGED; NETILMICIN; UROLOGIC DISEASES;

EID: 0038466313     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2003.01783.x     Document Type: Article

References (45)

1. Campoli-Richards DM, Chaplin S, Sayce RH, Goa KL. Netilmicin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1989; 38: 703-756.
2. Craig WA, Gudmundsson S, Reich RM. Netilmicin sulfate: a comparative evaluation of antimicrobial activity, pharmacokinetics, adverse reactions and clinical efficacy. Pharmacotherapy 1983; 3: 305-315.
3. Begg EJ, Barclay ML. Aminoglycosides. 50 years on. Br J Clin Pharmacol 1995; 39: 597-603.
4. Smith CR, Moore RD, Lietman PS. Studies of risk factors for aminoglycoside nephrotoxicity. Am J Kidney Dis 1986; 8: 308-313.
5. Cronberg S, Nordstrom L. Simplified monitoring of aminoglycoside treatment. Scand J Infect Dis Suppl 1990; 74: 274-279.
6. Blaser J, Rieder H, Niederer H, Luthy R. Biological variability of multiple dose pharmacokinetics of netilmicin in man. Eur J Clin Pharmacol 1983; 24: 399-406.
7. Ordovas JP, Ronchera CL, Poveda JL, Jimenez NV, Lopez R. Selection of optimal prophylactic aminoglycoside dosage in cancer patients: population pharmacokinetic approaches. J Clin Pharm Ther 1994; 19: 47-56.
8. Campbell D, Thomson AH, Stack B. Population pharmacokinetics of aminoglycoside antibiotics in patients with cystic fibrosis. Ther Drug Monit 1999; 21: 281-288.
9. Kummana CR, Yuen KY. Parenteral aminoglycoside therapy. Selection, administration and monitoring. Drugs 1994; 47: 902-913.
10. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987; 155: 93-99.
11. Barclay ML, Begg EJ. Once daily aminoglycoside therapy: Is it less toxic than multiple daily doses and how should it be monitored? Clin Pharmacokinet 1999; 36: 89-98.
12. Sawchuk R, Zaske D. Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: gentamicin in burn patient. J Pharmacokinet Biopharm 1976; 4: 183-195.
13. Sheiner LB, Beal S, Rosenberg T et al. Forecasting individual pharmacokinetics. Clin Pharmacol Ther 1979; 31: 294-305.
14. Burton ME, Brater C, Chen PS, Day RB, Huber PJ, Vasko MR. A Bayesian feed-back method of aminoglycoside dosing. Clin Pharmacol Ther 1985; 37: 349-357.
15. Garrafo R, Iliadis A, Cano JD, Dellamonica P, Lapalus P. Application of Bayesian estimation for the prediction of an appropriate dosage reginaen of amikacin. J Pharm Sci 1989; 78: 753-757.
16. Beal SL, Sheiner LB. The NONMEM system. Am Stat 1980; 34: 118-119.
17. Schumitzky A. Nonparametric EM algorithms for estimating prior distributions. Appl Math Comput 1991; 45: 143-157.
18. Treluyer JM, Merle Y, Semlali A, Pons G. Population pharmacokinetics analysis of netilmicin in neonates and infants with use of nonparametric method. Clin Pharmacol Ther 2000; 67: 600-609.
19. Aarons L, Vozeh S, Wenk M, Weiss PH, Follath F. Population pharmacokinetics of tobramycin. Br J Clin Pharmacol 1989; 28: 305-314.
20. Welling PG, Baumueller A, Lau CC, Madsen PO. Netilmicin pharmacokinetics after single intravenous doses to elderly male patients. Antimicrob Agents Chermother 1977; 12: 328-334.
21. Chang S, Li RC, Chan LSY et al. Netilmicin pharmacokinetics in Hong Kong Chinese cancer patients. Br J Clin Pharmacol 1999; 48: 33-35.
22. Pechere JC, Dugal R. Clinical pharmacokinetics of aminoglycoside antibiotics. Clin Pharmacokinet 1979; 4: 170-199.
23. Fattinger K, Vozeh S, Olafsson A, Vlcek J, Wenk M, Follath F. Netilmicin in the neonate: population pharmacokinetic analysis and dosing recommendations. Clin Pharmacol Ther 1991; 50: 55-65.
24. Kuhn RJ, Nahata MC, Powell DA, Bickers KG. Pharmacokinetics of netilmicin in premature infants. Eur J Clin Pharmacol 1986; 29: 635-637.
25. Darwish M, Batayneh M, Jenkins J, Scott M, Collier PS, McElnay JC. Prediction of netilmicin disposition in neonates. Biopharmaceutics Drug Disposition 1992; 13: 105-118.
26. Ettlinger JJ, Bedford KA, Lovering AM, Reeves DS, Speidel BD, McGowan AP. Pharmacokinetics of once-a-day netilmicin (6mg/kg) in neonates. J Antimicrob Chemother 1996; 38: 499-505.
27. Charton M, Vallencien B, Veillon V, Brisser JM. Antibiotic prophylaxis of urinary tract infection after resection of the prostate: a randomized study. J Urol 1987; 138: 87-89.
28. Minola E, Farina C, Zappone C, Arosio M, Lorenzi M, Mazzoni A. Short-term antibiotic prophylaxis for the prevention of wound infection and secondary meningitis in acoustic neuroma surgery: a ten-year experience in a regional hospital. J Chemother 2000; 12: 521-524.
29. Astobieta A, Calvo R, Aguirre C, Rodriguez-Sasiain JM. Netilmicin kinetics in urology. Int J Clin Pharmacol Ther Toxicol 1993; 31: 557-565.
30. Jolley ME, Stroupe SD, Wang C-HJ et al. Fluorescence polarization immunoassay, I. Monitoring aminoglycoside antibiotics in serum and plasma. Clin Chem 1981; 27: 1190-1197.
31. Mawer CE, Knowles BR, Lucas SB, Stirland RA, Tooth JA. Computer assisted prescribing of kanamycin for patients with renal insufficiency. Lancet 1972: 1: 12-15.
32. Koup JR, Killen T, Bawer LA. Multiple-dose, non-linear regression analysis program: aminoglycoside dose prediction. Clin Pharmacokinet 1983; 8: 456-462.
33. Koup JR, Horn J. Multiple-dose, nonlinear regression analysis program for the microcomputer. Ther Drug Monit 1984; 6: 51-57.
34. Robb RA, Bauer LA, Koup JR. Integrated calculator programs for pharmacokinetic calculations. Am J Hosp Phar 1982; 39: 825-828.
35. ABBOTTBASE Pharmacokinetic Systems. Operations Manual Illinois: ABBOTTBASE, 1991; 6.7.1.
36. Vozeh S, Maitre PO, Stanski DR. Evaluation of population (NONMEM) pharmacokinetic parameter estimates. J Pharmacokinet Biopharm 1990; 18: 161-173.
37. Kaufmann GR, Vozeh S, Wenk M, Haefeli WE. Safety and efficacy of a two-compartment Bayesian feedback program for therapeutic tobramycin monitoring in the daily clinical use and comparison with a non-Bayesian one-compartment model. Ther Drug Monitor 1998; 20: 172-180.
38. Vozeh S, Spring P, Wenk M, Follath F. Changes in the apparent half life of gentamicin and tobramycin without detectable changes in creatinine clearance. Br J Clin Pharmacol 1979; 7: 629-631.
39. Wenk M, Spring P, Vozeh S, Follath F. Multicompartment pharmacokinetics of netilmicin. Eur J Clin Pharmacol 1979; 16: 331-334.
40. Xuan D, Lu J, Nicolau DP, Nightingale CH. Population pharmacokinetics of tobramycin in hospitalized patients receiving once-daily dosing regimen. Int J Antimicrob Agents 2000; 15: 185-191.
41. McNamara DR, Nafziger AN, Menhinick AM, Bertino JS. A dose-ranging study of gentamicin pharmacokinetics: implications for extended interval aminoglycoside therapy. J Clin Pharmacol 2001; 41: 374-377.
42. Charton M, Vallencien B, Veillon V, Brisser JM. Antibiotic prophylaxis of urinary tract infection after resection of the prostate: a randomized study. J Urol 1987; 17: 87-89.
43. Luft FC, Brannon DR, Stropes LL. Pharmacokinetics of netilmicin in patients with renal impairment and in patients on dialysis. Antimicrob Agents Chemother 1978; 14: 403-407.
44. Humbert G. Leroy A, Fillastre JP. Pharmacokinetics of netilmicin in the presence of normal or impaired renal function. Antimicrob Agents Chemother 1978; 14: 40-44.
45. Miholic J, Reilmann L, Meyer HJ, Korber H, Diecklemann A, Pichlmayr R. Estimation of extracellular space and blood volume using bioelectrical impedance measurements. Clin Invest 1992; 70: 600-605.